Skip to content
All peptides
KISS1R agonist (hypothalamic neuropeptide)

Kisspeptin

Also known as: Kisspeptin-54, Kisspeptin-10, KP-54, KP-10, Metastin

Tier 2 — Human observationalReviewed 2026-05-04

Upstream of the entire reproductive axis — triggers GnRH, then LH/FSH, then sex hormones. Tier 1 in clinical research settings (Imperial / Dhillo lab) for hypogonadism and IVF; Tier 3 for off-label 'natural T' community use.

Loading the AI assistant…

Overview

Kisspeptin is the endogenous neuropeptide that sits at the very top of the reproductive axis — KISS1R agonism on hypothalamic neurons is the trigger for GnRH release, which drives pituitary LH/FSH, which drives gonadal sex steroid production. Loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism. The Imperial College London / Dhillo lab has built the bulk of the clinical kisspeptin literature over the past decade — pulsatile dosing for hypothalamic amenorrhea, oocyte maturation in IVF, exploration in hypogonadotropic hypogonadism, and characterization in normal physiology. Multiple well-designed clinical research trials exist, mostly in academic-research settings rather than as approved drugs. Community off-label use of kisspeptin as a 'natural testosterone booster' rests on plausible upstream mechanism but no clinical-outcome data in healthy hypogonadism-free adults. The split is real and the entry must hold it.

Mechanism

Agonist at KISS1R (also known as GPR54), a Gq-coupled GPCR expressed on hypothalamic GnRH neurons. KISS1R activation drives GnRH secretion, which in turn stimulates pituitary LH and FSH release, which then drives testicular testosterone synthesis (in men) and ovarian steroidogenesis and ovulation (in women). In the IVF context, a single bolus of kisspeptin-54 has been shown to trigger oocyte maturation comparable to standard hCG triggers, with potentially lower OHSS risk. Active fragments include the full 54-residue form and the C-terminal 10-residue minimal active fragment (KP-10).

Evidence by indication

We classify each indication separately. The same peptide can be Tier 1 for one use and Tier 4 for another. Tiers reflect the published literature, not the strength of community framing.

Hypothalamic amenorrhea — restoration of menstrual cyclicity

Tier 2high confidence

Imperial College / Dhillo lab studies (Jayasena 2014 and follow-ups) demonstrated pulsatile kisspeptin can restore LH pulsatility and menstrual function in women with hypothalamic amenorrhea. Replicated within the same lab system, not yet at multicenter Phase 3 scale. Strong Tier 2.

Jayasena CN et al. 2014

IVF oocyte maturation trigger (alternative to hCG)

Tier 2high confidence

Multiple Phase 2 studies (Abbara, Dhillo lab) demonstrated kisspeptin-54 effectively triggers oocyte maturation in IVF cycles with potentially lower ovarian hyperstimulation syndrome (OHSS) risk than standard hCG triggers. Strong Tier 2 in this specific clinical-research context.

Abbara A et al. 2015

Hypogonadotropic hypogonadism (men) — endogenous T elevation

Tier 2medium confidence

Studies in men with hypogonadotropic hypogonadism show kisspeptin restores LH pulsatility and downstream T production. Limited to research populations; no approved clinical use.

Jayasena CN et al. 2014

Off-label 'natural testosterone booster' in eugonadal men

Tier 3high confidence

Community/clinic use as a non-suppressive alternative to TRT in healthy men rests on plausible upstream mechanism but no clinical-outcome data in eugonadal adults. The Tier 1/2 evidence in hypogonadism does NOT propagate to use in men with normal baseline T (Skill Rule 6).

No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.

Sexual desire / arousal (independent of T elevation)

Tier 3medium confidence

Some research-context evidence that kisspeptin modulates limbic arousal circuits independent of its endocrine effects. Small-cohort fMRI / behavioral studies. Not yet a clinical indication.

No primary citations are anchored to this indication — the tier reflects the absence of usable literature, not a missing reference.

Studied dose ranges

The ranges below come from published trial protocols where available, and from documented self-experimenter consensus where the literature does not include human dose-finding work. The notes flag which is which.

1–12 mcgpulsatile (e.g., every 90 minutes for hypothalamic amenorrhea) · subcutaneous (research)

Imperial College pulsatile-SubQ kisspeptin-54 protocols cluster at ~6.4–12.8 mcg per pulse delivered every ~90 minutes. Note these are clinical research protocols, not commercial dosing.

100–1,000 mcgsingle bolus · subcutaneous (IVF oocyte maturation trigger, research)

IVF research bolus dosing typically 1.6–9.6 nmol/kg of kisspeptin-54 for ovulation triggering. Translation to a fixed mcg dose depends on body weight; representative adult bolus is ~100–1000 mcg.

Contraindications

  • Pregnancy (outside specific IVF research context under specialist supervision)
  • Hormone-sensitive malignancy (theoretical concern from sex-steroid axis stimulation)
  • Concurrent use with GnRH agonists/antagonists or fertility-treatment regimens without specialist supervision
  • Known hypersensitivity to peptide formulations

Reported side effects

  • Generally well tolerated in research-clinical use
  • Injection-site reactions
  • Headache
  • Transient elevations in LH / FSH / sex steroids (the on-target effect)
  • Theoretical: induction or precipitation of ovulation in unintended contexts
  • OHSS risk in IVF context appears lower than with hCG triggers but is not zero
  • Long-term safety in non-research populations is unstudied

Reconstitution & storage

Lyophilized powder reconstituted with bacteriostatic water. Concentrations vary by vendor and active fragment (KP-54 vs KP-10) — verify per batch. Imperial-style pulsatile SubQ research dosing requires careful concentration math and a pump or programmed dosing schedule; this is not a 'set-and-forget' weekly peptide.

Storage. Lyophilized: refrigerate. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Open the peptide calculator → to compute exact draw volumes for your specific vial and BAC water choice.

Editorial note

DRAFT — pending Wayne's review. Kisspeptin is one of the more scientifically substantive entries in this batch — there's a credible academic clinical literature, mostly out of one prolific lab system. Hold the line on the indication split: Tier 2 for reproductive-medicine research applications (hypothalamic amenorrhea, IVF, hypogonadism) and Tier 3 for the wellness-clinic 'natural testosterone' framing in eugonadal men. The same molecule can have both tiers and that's the point of the framework.

Citations

  1. [1]
    Twice-daily subcutaneous injection of kisspeptin-54 does not abolish menstrual cyclicity in healthy female volunteers
    Jayasena CN, Abbara A, Veldhuis JD, et al. · Journal of Clinical Investigation · 2014 · PMID 25313274
    Anchor Imperial College kisspeptin clinical work supporting Tier 2 framing in reproductive-axis indications.
    View source
  2. [2]
    Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy
    Abbara A, Jayasena CN, Christopoulos G, et al. · Journal of Clinical Endocrinology & Metabolism · 2015 · PMID 25822128
    Tier 2 anchor for the IVF oocyte-maturation indication.
    View source